{"id":1546,"date":"2025-10-12T20:27:51","date_gmt":"2025-10-13T00:27:51","guid":{"rendered":"https:\/\/www.madischu.com\/?p=1546"},"modified":"2025-10-12T20:27:51","modified_gmt":"2025-10-13T00:27:51","slug":"gut-dysbiosis-in-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/www.life360coach.com\/index.php\/2025\/10\/12\/gut-dysbiosis-in-parkinsons-disease\/","title":{"rendered":"Gut Dysbiosis in Parkinson’s Disease"},"content":{"rendered":"
\n
\n
\n
Gut dysbiosis is characterized by reduced microbial diversity and shifts in bacterial composition.
\nIt is a prominent feature in Parkinson’s disease (PD), often preceding motor symptoms by years and contributing to disease initiation and progression via the microbiota-gut-brain axis.
\nPD patients exhibit consistent alterations, including depletion of short-chain fatty acid (SCFA)-producing bacteria and enrichment of pro-inflammatory taxa, which correlate with gastrointestinal symptoms (e.g., constipation), non-motor issues (e.g., depression, sleep disturbances), and motor severity (e.g., UPDRS scores).
\nThese changes are influenced by factors like disease duration, medications, diet, and geography, with emerging evidence from 2024\u20132025 studies supporting a “gut-first” model.
\nIn this model, dysbiosis drives \u03b1-synuclein pathology, neuroinflammation, and dopaminergic neuron loss.
\nLongitudinal profiling and fecal microbiota transplantation (FMT) models underscore causality, positioning dysbiosis as a modifiable target for early intervention.<\/p>\n

<\/span><\/span><\/span>Microbial Alterations in PD<\/strong>
\n<\/span><\/span><\/span>Meta-analyses and cohort studies reveal reproducible patterns, though alpha diversity reductions are often non-significant due to confounders.
\nKey shifts include decreased beneficial, anti-inflammatory genera and increased opportunistic pathogens, with fecal short-chain fatty acids (SCFA)\u00a0 levels (e.g., butyrate) reduced by 20\u201350%.<\/p>\n

<\/span><\/span><\/span><\/p>\n

\n\n\n\n\n\n\n
\n
Pattern<\/span><\/span><\/div>\n<\/th>\n
\n
Key Taxa Changes<\/span><\/span><\/div>\n<\/th>\n
\n
Correlations & Evidence<\/span><\/span><\/div>\n<\/th>\n<\/tr>\n
\n
Reduced Diversity & Beneficial Depletion<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
\u2193 <\/span><\/span>Faecalibacterium prausnitzii<\/span><\/span><\/span>, <\/span><\/span>Roseburia<\/span><\/span><\/span> spp., <\/span><\/span>Blautia<\/span><\/span><\/span>, <\/span><\/span>Prevotella<\/span><\/span><\/span>, <\/span><\/span>Butyricicoccus<\/span><\/span><\/span>, <\/span><\/span>Lachnospiraceae<\/span><\/span><\/span> family; non-significant \u2193 alpha diversity (Shannon index)<\/span><\/span><\/div>\n<\/td>\n
\n
Lower SCFA production correlates with constipation, disease progression (e.g., Hoehn & Yahr stage), and motor\/non-motor symptoms (NMSS scores \u2191); observed in fecal\/ileal samples from PD (n=44) vs. HC (n=21).<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n
\n
Pro-Inflammatory Enrichment<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
\u2191 <\/span><\/span>Lactobacillus<\/span><\/span><\/span>, <\/span><\/span>Streptococcus<\/span><\/span><\/span>, <\/span><\/span>Akkermansia<\/span><\/span><\/span>, <\/span><\/span>Bifidobacterium<\/span><\/span><\/span> (non-significant), <\/span><\/span>Enterobacteriaceae<\/span><\/span><\/span> (e.g., <\/span><\/span>Klebsiella<\/span><\/span><\/span>, <\/span><\/span>Escherichia coli<\/span><\/span><\/span>, <\/span><\/span>Proteus<\/span><\/span><\/span>), <\/span><\/span>Bilophila<\/span><\/span><\/span>, <\/span><\/span>Parabacteroides<\/span><\/span><\/span>, <\/span><\/span>Verrucomicrobia<\/span><\/span><\/span>, <\/span><\/span>Oscillospiraceae<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
Increased gut permeability and inflammation (fecal calprotectin \u2191); links to \u03b1-syn aggregation and motor deficits (e.g., beam walking time \u2191 in FMT models); ileal SFB erosion in PD mice\/patients.<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n
\n
Other Shifts<\/span><\/span><\/span><\/div>\n<\/td>\n
\n
\u2193 Segmented filamentous bacteria (SFB) in ileum; variable <\/span><\/span>Bifidobacterium<\/span><\/span><\/span> (depleted in ileal biopsies)<\/span><\/span><\/div>\n<\/td>\n
\n
Disrupts Th17 homeostasis; precedes systemic inflammation; consistent in single\/multiple-donor FMT paradigms.<\/span><\/span><\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n


\nKey Mechanisms:<\/strong>
\n<\/span><\/span><\/span>Dysbiosis initiates a cascade from gut to brain, with bidirectional gut-brain signaling via vagus nerve, metabolites, and immune cells.<\/span><\/span><\/span><\/p>\n